Head-To-Head Contrast: Digiliti Money (DGLT) versus CareDx (CDNA)

Digiliti Money (OTCMKTS: DGLT) and CareDx (NASDAQ:CDNA) are both small-cap business services companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability and risk.

Insider and Institutional Ownership

11.3% of Digiliti Money shares are owned by institutional investors. Comparatively, 23.2% of CareDx shares are owned by institutional investors. 50.9% of Digiliti Money shares are owned by insiders. Comparatively, 5.4% of CareDx shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Digiliti Money and CareDx, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Digiliti Money 0 0 1 0 3.00
CareDx 0 0 4 0 3.00

Digiliti Money currently has a consensus target price of $6.00, suggesting a potential upside of 3,057.89%. CareDx has a consensus target price of $8.88, suggesting a potential upside of 24.65%. Given Digiliti Money’s higher possible upside, equities analysts plainly believe Digiliti Money is more favorable than CareDx.

Earnings & Valuation

This table compares Digiliti Money and CareDx’s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Digiliti Money $7.97 million 0.24 -$15.16 million ($6.05) -0.03
CareDx $40.63 million 5.01 -$39.46 million ($1.81) -3.93

Digiliti Money has higher earnings, but lower revenue than CareDx. CareDx is trading at a lower price-to-earnings ratio than Digiliti Money, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Digiliti Money has a beta of -1.62, suggesting that its share price is 262% less volatile than the S&P 500. Comparatively, CareDx has a beta of 1.03, suggesting that its share price is 3% more volatile than the S&P 500.

Profitability

This table compares Digiliti Money and CareDx’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Digiliti Money -147.73% N/A -199.21%
CareDx -84.14% -157.00% -23.52%

Summary

CareDx beats Digiliti Money on 8 of the 12 factors compared between the two stocks.

About Digiliti Money

Digiliti Money Group, Inc., formerly Digiliti Money, Inc., is a technology solutions and services provider to the financial services industry. The Company’s solutions and services enable its clients, such as banks, credit unions and alternative financial services providers (AFS) to offer their customers remote deposit capture (RDC) and prepaid mobile money technologies and related services. It offers RDC products for businesses and consumers; mobile money management products for consumers, and training and support services for its financial services industry customers. The RDC products are offered to banks and credit unions in the United States, Canada and Latin America. Its mobile money management products are offered to traditional financial institutions (FIs), as well as AFS in the United States, Canada and Latin America. These FIs and AFS providers include banks, credit unions, prepaid card issuers, check cashers and payday lenders.

About CareDx

CareDx, Inc. is a molecular diagnostics company. The Company is focused on the discovery, development and commercialization of clinically differentiated diagnostic surveillance solutions for transplant patients. The Company’s commercialized testing solution, the AlloMap heart transplant molecular test (AlloMap), is a gene expression test that helps clinicians monitor and identify heart transplant recipients with stable graft function having a low probability of moderate/severe acute cellular rejection. Its products under development for transplant monitoring include AlloSure, a development-stage transplant surveillance solution, which applies next generation sequencing to detect and quantitate genetic differences between donor-derived cell-free deoxyribonucleic acid (dd-cfDNA) in the blood stream emanating from the donor heart. It offers the AlloMap Score Variability service, which provides complementary information to help personalize long-term care of heart transplant recipients.

Receive News & Ratings for Digiliti Money Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Digiliti Money and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply